查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
器官移植排斥反应药物市场 - 2022-2031年全球行业分析、规模、份额、增长、趋势和预测
市场调查报告书
商品编码
1301470

器官移植排斥反应药物市场 - 2022-2031年全球行业分析、规模、份额、增长、趋势和预测

Organ Transplant Rejection Medication Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 241 Pages | 商品交期: 2-10个工作天内

价格

器官移植排斥反应药物市场 - 报告范围

TMR关于全球器官移植排斥反应药物市场的报告研究了过去以及当前的增长趋势和机会，以获得对2023年至2031年预测期间的市场指标的宝贵见解。报告提供了2017-2031年期间全球器官移植排斥反应药物市场的收入，考虑到2023年为基准年，2031年为预测年。报告还提供了2023年至2031年全球器官移植排斥药物治疗市场的复合年增长率（CAGR %）。

该报告是在广泛的研究后编写的。一级研究涉及大部分的研究工作，其中分析师与关键意见领袖、行业领袖和意见制造者进行了访谈。二级研究包括参考主要参与者的产品资料、年度报告、新闻稿和相关文件，以了解器官移植排斥反应药物的市场。

报告深入研究了全球器官移植排斥反应药物市场的竞争格局。已经确定了在全球器官移植排异反应药物治疗市场运作的主要参与者，并对其中每一个参与者的各种属性进行了分析。公司概况、财务状况、最近的发展和SWOT是本报告中对全球器官移植排斥药物治疗市场参与者的属性描述。

目录

第一章：前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 研究重点

第二章：假设和研究方法

第三章：执行摘要：全球市场

第四章：市场概述

  • 简介
    • 细分市场的定义
  • 概述
  • 市场动态
    • 驱动力
    • 限制因素
    • 机会
  • 2017-2031年全球市场分析与预测

第五章：关键洞察力

  • 当前的全球情况：移植用器官捐献
  • 主要产品/品牌分析
  • 管线分析
  • COVID-19影响分析

第六章：全球市场分析与预测：按药物类别分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按药物类别，2017-2031年
    • 抗体
      • 胸腺球蛋白
      • Alemtuzumab
      • 贝拉塔普
      • 穆罗单抗-CD3
      • 巴西利希单抗
      • 艾库利珠单抗
    • 抗代谢药物
      • 硫唑嘌呤
      • 霉酚酸酯（Mycophenolate Mofetil
      • 霉酚酸钠，MPA
    • 钙素酶抑制剂
      • 环孢素
      • 他克莫司
    • mTOR抑制剂
      • 西罗莫司
      • 埃沃利姆斯
    • 类固醇
      • 泼尼松龙
      • 甲基泼尼松龙
  • 市场吸引力分析：按药物类别

第七章 ：全球市场分析与预测：按移植类型分类

  • 介绍和定义
  • 主要研究结果/发展
  • 市场价值预测：按移植类型，2017-2031年
    • 肾脏
    • 肝脏
    • 心脏
    • 肺脏
    • 胰腺
    • 其他类型
  • 市场吸引力分析：按移植类型

第八章：全球市场分析与预测：按分销渠道分类

  • 介绍和定义
  • 主要研究结果/发展
  • 市场价值预测：按分销渠道划分，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场吸引力分析：按分销渠道分类

第九章：全球市场分析与预测：按地区分类

  • 主要发现
  • 市场价值预测：按地区划分，2017-2031年
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第十章：北美市场分析与预测

  • 简介
    • 主要研究结果
  • 市场价值预测：按药物类别，2017-2031年
    • 抗体
      • 胸腺球蛋白
      • 阿仑珠单抗
      • 贝拉塔普
      • 穆罗单抗-CD3
      • 巴西利希单抗
      • 艾库利珠单抗
    • 抗代谢药物
      • 硫唑嘌呤
      • 霉酚酸酯（Mycophenolate Mofetil
      • 霉酚酸钠，MPA
    • 钙素酶抑制剂
      • 环孢素
      • 他克莫司
    • mTOR抑制剂
      • 西罗莫司
      • 埃沃利姆斯
    • 类固醇
      • 泼尼松龙
      • 甲基泼尼松龙
  • 市场价值预测：按移植类型，2017-2031年
    • 肾脏
    • 肝脏
    • 心脏
    • 肺脏
    • 胰腺
    • 其他
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家划分，2017-2031年
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按药物类别
    • 按移植类型分类
    • 按分销渠道分类
    • 按国家分类

第11章 ：欧洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 抗体
      • 胸腺球蛋白
      • 阿仑珠单抗
      • 贝拉塔普
      • 穆罗单抗-CD3
      • 巴西利希单抗
      • 艾库利珠单抗
    • 抗代谢药物
      • 硫唑嘌呤
      • 霉酚酸酯（Mycophenolate Mofetil
      • 霉酚酸钠，MPA
    • 钙素酶抑制剂
      • 环孢素
      • 他克莫司
    • mTOR抑制剂
      • 西罗莫司
      • 埃沃利姆斯
    • 类固醇
      • 泼尼松龙
      • 甲基泼尼松龙
  • 市场价值预测：按移植类型，2017-2031年
    • 肾脏
    • 肝脏
    • 心脏
    • 肺脏
    • 胰腺
    • 其他
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按移植类型分类
    • 按分销渠道分类
    • 按国家/次区域分类

第十二章 ：亚太地区市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 抗体
      • 胸腺球蛋白
      • 阿仑珠单抗
      • 贝拉塔普
      • 穆罗单抗-CD3
      • 巴西利希单抗
      • 艾库利珠单抗
    • 抗代谢药物
      • 硫唑嘌呤
      • 霉酚酸酯（Mycophenolate Mofetil
      • 霉酚酸钠，MPA
    • 钙素酶抑制剂
      • 环孢素
      • 他克莫司
    • mTOR抑制剂
      • 西罗莫司
      • 埃沃利姆斯
    • 类固醇
      • 泼尼松龙
      • 甲基泼尼松龙
  • 市场价值预测：按移植类型，2017-2031年
    • 肾脏
    • 肝脏
    • 心脏
    • 肺脏
    • 胰腺
    • 其他
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 中国
    • 日本
    • 印度
    • 澳大利亚和新西兰
    • 亚太其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按移植类型
    • 按分销渠道
    • 按国家/次区域分类

第13章 ：拉美市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 抗体
      • 胸腺球蛋白
      • 阿仑珠单抗
      • 贝拉塔普
      • 穆罗单抗-CD3
      • 巴西利希单抗
      • 艾库利珠单抗
    • 抗代谢药物
      • 硫唑嘌呤
      • 霉酚酸酯（Mycophenolate Mofetil
      • 霉酚酸钠，MPA
    • 钙素酶抑制剂
      • 环孢素
      • 他克莫司
    • mTOR抑制剂
      • 西罗莫司
      • 埃沃利姆斯
    • 类固醇
      • 泼尼松龙
      • 甲基泼尼松龙
  • 市场价值预测：按移植类型，2017-2031年
    • 肾脏
    • 肝脏
    • 心脏
    • 肺脏
    • 胰腺
    • 其他
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 巴西
    • 墨西哥
    • 拉美其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按移植类型分类
    • 按分销渠道分类
    • 按国家/次区域分类

第十四章：中东和非洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按药物类别，2017-2031年
    • 抗体
      • 胸腺球蛋白
      • 阿仑珠单抗
      • 贝拉塔普
      • 穆罗单抗-CD3
      • 巴西利希单抗
      • 艾库利珠单抗
    • 抗代谢药物
      • 硫唑嘌呤
      • 霉酚酸酯（Mycophenolate Mofetil
      • 霉酚酸钠，MPA
    • 钙素酶抑制剂
      • 环孢素
      • 他克莫司
    • mTOR抑制剂
      • 西罗莫司
      • 埃沃利姆斯
    • 类固醇
      • 泼尼松龙
      • 甲基泼尼松龙
  • 市场价值预测：按移植类型，2017-2031年
    • 肾脏
    • 肝脏
    • 心脏
    • 肺脏
    • 胰腺
    • 其他
  • 市场价值预测：按分销渠道，2017-2031年
    • 医院药房
    • 零售药店
    • 网上药店
  • 市场价值预测：按国家/次区域划分，2017-2031年
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区
  • 市场吸引力分析
    • 按药物类别
    • 按移植类型分类
    • 按分销渠道分类
    • 按国家/次区域分类

第十五章 ：竞争格局

  • 市场参与者 - 竞争矩阵（按公司的层级和规模划分）
  • 市场份额分析：按公司分类 (2022)
  • 公司简介
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • AbbVie, Inc.
    • Hansa Biopharma
    • WOCKHARDT
    • Viatris, Inc.
    • Glenmark
    • Biocon
    • Hikma Pharmaceuticals plc
    • Teva Pharmaceutical U.S.A Inc.
    • Zydus Pharmaceuticals, Inc.
Product Code: TMRGL76123

Organ Transplant Rejection Medication Market - Scope of Report

TMR's report on the global Organ Transplant Rejection Medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Organ Transplant Rejection Medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Organ Transplant Rejection Medication market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Organ Transplant Rejection Medication market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Organ Transplant Rejection Medication market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Organ Transplant Rejection Medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Organ Transplant Rejection Medication market.

The report delves into the competitive landscape of the global Organ Transplant Rejection Medication market. Key players operating in the global Organ Transplant Rejection Medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Organ Transplant Rejection Medication market profiled in this report.

Key Questions Answered in Global Organ Transplant Rejection Medication Market Report:

  • What is the sales/revenue generated by Organ Transplant Rejection Medication across all regions during the forecast period?
  • What are the opportunities in the global Organ Transplant Rejection Medication market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Organ Transplant Rejection Medication Market - Research Objectives and Research Approach

The comprehensive report on the global Organ Transplant Rejection Medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Organ Transplant Rejection Medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Organ Transplant Rejection Medication market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Organ Transplant Rejection Medication Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Current Global Scenario: Organ Donation for Transplantation
  • 5.2. Key Product/Brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Impact Analysis

6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Antibodies
      • 6.3.1.1. Thymoglobulin
      • 6.3.1.2. Alemtuzumab
      • 6.3.1.3. Belatacept
      • 6.3.1.4. Muromonab-CD3
      • 6.3.1.5. Basiliximab
      • 6.3.1.6. Eculizumab
    • 6.3.2. Antimetabolites
      • 6.3.2.1. Azathioprine
      • 6.3.2.2. Mycophenolate Mofetil
      • 6.3.2.3. Mycophenolate sodium, MPA
    • 6.3.3. Calcineurin Inhibitors
      • 6.3.3.1. Cyclosporine
      • 6.3.3.2. Tacrolimus
    • 6.3.4. mTOR Inhibitors
      • 6.3.4.1. Sirolimus
      • 6.3.4.2. Everolimus
    • 6.3.5. Steroids
      • 6.3.5.1. Prednisolone
      • 6.3.5.2. Methylprednisolone
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 7.3.1. Kidney
    • 7.3.2. Liver
    • 7.3.3. Heart
    • 7.3.4. Lung
    • 7.3.5. Pancreas
    • 7.3.6. Others
  • 7.4. Market Attractiveness Analysis, by Transplant Type

8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Antibodies
      • 10.2.1.1. Thymoglobulin
      • 10.2.1.2. Alemtuzumab
      • 10.2.1.3. Belatacept
      • 10.2.1.4. Muromonab-CD3
      • 10.2.1.5. Basiliximab
      • 10.2.1.6. Eculizumab
    • 10.2.2. Antimetabolites
      • 10.2.2.1. Azathioprine
      • 10.2.2.2. Mycophenolate Mofetil
      • 10.2.2.3. Mycophenolate sodium, MPA
    • 10.2.3. Calcineurin Inhibitors
      • 10.2.3.1. Cyclosporine
      • 10.2.3.2. Tacrolimus
    • 10.2.4. mTOR Inhibitors
      • 10.2.4.1. Sirolimus
      • 10.2.4.2. Everolimus
    • 10.2.5. Steroids
      • 10.2.5.1. Prednisolone
      • 10.2.5.2. Methylprednisolone
  • 10.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 10.3.1. Kidney
    • 10.3.2. Liver
    • 10.3.3. Heart
    • 10.3.4. Lung
    • 10.3.5. Pancreas
    • 10.3.6. Others
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Transplant Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Antibodies
      • 11.2.1.1. Thymoglobulin
      • 11.2.1.2. Alemtuzumab
      • 11.2.1.3. Belatacept
      • 11.2.1.4. Muromonab-CD3
      • 11.2.1.5. Basiliximab
      • 11.2.1.6. Eculizumab
    • 11.2.2. Antimetabolites
      • 11.2.2.1. Azathioprine
      • 11.2.2.2. Mycophenolate Mofetil
      • 11.2.2.3. Mycophenolate sodium, MPA
    • 11.2.3. Calcineurin Inhibitors
      • 11.2.3.1. Cyclosporine
      • 11.2.3.2. Tacrolimus
    • 11.2.4. mTOR Inhibitors
      • 11.2.4.1. Sirolimus
      • 11.2.4.2. Everolimus
    • 11.2.5. Steroids
      • 11.2.5.1. Prednisolone
      • 11.2.5.2. Methylprednisolone
  • 11.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 11.3.1. Kidney
    • 11.3.2. Liver
    • 11.3.3. Heart
    • 11.3.4. Lung
    • 11.3.5. Pancreas
    • 11.3.6. Others
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Transplant Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Antibodies
      • 12.2.1.1. Thymoglobulin
      • 12.2.1.2. Alemtuzumab
      • 12.2.1.3. Belatacept
      • 12.2.1.4. Muromonab-CD3
      • 12.2.1.5. Basiliximab
      • 12.2.1.6. Eculizumab
    • 12.2.2. Antimetabolites
      • 12.2.2.1. Azathioprine
      • 12.2.2.2. Mycophenolate Mofetil
      • 12.2.2.3. Mycophenolate sodium, MPA
    • 12.2.3. Calcineurin Inhibitors
      • 12.2.3.1. Cyclosporine
      • 12.2.3.2. Tacrolimus
    • 12.2.4. mTOR Inhibitors
      • 12.2.4.1. Sirolimus
      • 12.2.4.2. Everolimus
    • 12.2.5. Steroids
      • 12.2.5.1. Prednisolone
      • 12.2.5.2. Methylprednisolone
  • 12.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 12.3.1. Kidney
    • 12.3.2. Liver
    • 12.3.3. Heart
    • 12.3.4. Lung
    • 12.3.5. Pancreas
    • 12.3.6. Others
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Transplant Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Antibodies
      • 13.2.1.1. Thymoglobulin
      • 13.2.1.2. Alemtuzumab
      • 13.2.1.3. Belatacept
      • 13.2.1.4. Muromonab-CD3
      • 13.2.1.5. Basiliximab
      • 13.2.1.6. Eculizumab
    • 13.2.2. Antimetabolites
      • 13.2.2.1. Azathioprine
      • 13.2.2.2. Mycophenolate Mofetil
      • 13.2.2.3. Mycophenolate sodium, MPA
    • 13.2.3. Calcineurin Inhibitors
      • 13.2.3.1. Cyclosporine
      • 13.2.3.2. Tacrolimus
    • 13.2.4. mTOR Inhibitors
      • 13.2.4.1. Sirolimus
      • 13.2.4.2. Everolimus
    • 13.2.5. Steroids
      • 13.2.5.1. Prednisolone
      • 13.2.5.2. Methylprednisolone
  • 13.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 13.3.1. Kidney
    • 13.3.2. Liver
    • 13.3.3. Heart
    • 13.3.4. Lung
    • 13.3.5. Pancreas
    • 13.3.6. Others
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Transplant Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Antibodies
      • 14.2.1.1. Thymoglobulin
      • 14.2.1.2. Alemtuzumab
      • 14.2.1.3. Belatacept
      • 14.2.1.4. Muromonab-CD3
      • 14.2.1.5. Basiliximab
      • 14.2.1.6. Eculizumab
    • 14.2.2. Antimetabolites
      • 14.2.2.1. Azathioprine
      • 14.2.2.2. Mycophenolate Mofetil
      • 14.2.2.3. Mycophenolate sodium, MPA
    • 14.2.3. Calcineurin Inhibitors
      • 14.2.3.1. Cyclosporine
      • 14.2.3.2. Tacrolimus
    • 14.2.4. mTOR Inhibitors
      • 14.2.4.1. Sirolimus
      • 14.2.4.2. Everolimus
    • 14.2.5. Steroids
      • 14.2.5.1. Prednisolone
      • 14.2.5.2. Methylprednisolone
  • 14.3. Market Value Forecast, by Transplant Type, 2017-2031
    • 14.3.1. Kidney
    • 14.3.2. Liver
    • 14.3.3. Heart
    • 14.3.4. Lung
    • 14.3.5. Pancreas
    • 14.3.6. Others
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Transplant Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer, Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Product Portfolio
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Astellas Pharma, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Product Portfolio
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. Novartis AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Product Portfolio
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. F. Hoffmann-La Roche Ltd.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Product Portfolio
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Sanofi
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Product Portfolio
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Product Portfolio
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. GlaxoSmithKline plc
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Product Portfolio
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. AbbVie, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Product Portfolio
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. Hansa Biopharma
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Product Portfolio
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. WOCKHARDT
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Business Strategies
      • 15.3.10.4. Recent Developments
    • 15.3.11. Viatris, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Product Portfolio
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Glenmark
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Product Portfolio
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
    • 15.3.13. Biocon
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Product Portfolio
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Developments
    • 15.3.14. Hikma Pharmaceuticals plc
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Financial Overview
      • 15.3.14.3. Product Portfolio
      • 15.3.14.4. Business Strategies
      • 15.3.14.5. Recent Developments
    • 15.3.15. Teva Pharmaceutical U.S.A Inc.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Financial Overview
      • 15.3.15.3. Product Portfolio
      • 15.3.15.4. Business Strategies
      • 15.3.15.5. Recent Developments
    • 15.3.16. Zydus Pharmaceuticals, Inc.
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Financial Overview
      • 15.3.16.3. Product Portfolio
      • 15.3.16.4. Business Strategies
      • 15.3.16.5. Recent Developments

List of Tables

  • Table 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 11: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 12: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 13: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 14: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 15: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 16: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 17: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 19: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 20: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 21: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 22: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 23: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 24: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 25: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 26: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 27: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 28: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 29: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 30: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 31: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 32: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 33: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 34: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 35: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 36: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 37: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 38: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 39: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 40: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 41: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 42: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 43: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 44: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 45: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 46: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 47: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017-2031
  • Table 48: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017-2031
  • Table 49: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017-2031
  • Table 50: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017-2031
  • Table 51: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017-2031
  • Table 52: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
  • Table 53: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 54: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Organ Transplant Rejection Medications Market Value Share, by Drug Class, 2022
  • Figure 03: Global Organ Transplant Rejection Medications Market Value Share, by Transplant Type, 2022
  • Figure 04: Global Organ Transplant Rejection Medications Market Value Share, by Distribution Channel, 2022
  • Figure 05: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 06: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antibodies, 2017-2031
  • Figure 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antimetabolites, 2017-2031
  • Figure 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Calcineurin Inhibitors, 2017-2031
  • Figure 10: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by mTOR Inhibitors, 2017-2031
  • Figure 11: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Steroids, 2017-2031
  • Figure 12: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 13: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 14: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Kidney, 2017-2031
  • Figure 15: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Liver, 2017-2031
  • Figure 16: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Heart, 2017-2031
  • Figure 17: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Lung, 2017-2031
  • Figure 18: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Pancreas, 2017-2031
  • Figure 19: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 20: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 21: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 22: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 23: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 27: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 29: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 30: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 31: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 32: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 35: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 36: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 38: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 39: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 40: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 41: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 43: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 47: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 49: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 50: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 51: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 52: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 53: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 54: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 55: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 56: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 57: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 58: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 59: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 60: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 61: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 62: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 63: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 64: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 65: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 66: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
  • Figure 67: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
  • Figure 68: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 69: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 70: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 71: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031